Pseudomonas aeruginosa Infections Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Pseudomonas aeruginosa Infections Clinical Trial Analysis research report provides an overview of Pseudomonas aeruginosa Infections Clinical trials scenario. This report provides top-line data relating to the clinical trials on Pseudomonas aeruginosa Infections. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The report also provides prominent drugs for in-progress trials.
What is the regional and country-wise outlook in the Pseudomonas aeruginosa Infections clinical trials market?
The Pseudomonas aeruginosa Infections clinical trials market is the largest in Europe, followed by, North America, Asia Pacific, the Middle East and Africa, and South and Central America. In a country-wise analysis, as of May 2022, the US has the highest number of Pseudomonas aeruginosa Infections clinical trials, followed by the UK, Germany, Australia, Spain, France, Canada, Italy, Poland, and Belgium. Belgium has the highest average patient enrollment in Pseudomonas aeruginosa Infections clinical trials.
G7 countries:
Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, Germany has the highest proportion of Pseudomonas aeruginosa Infections to Infectious Disease clinical trials. Moreover, out of all the clinical trials conducted in the G7 countries, the majority were in the US.
E7 countries:
Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Russia has the highest proportion of Pseudomonas aeruginosa Infections to Infectious Disease clinical trials. Out of all the clinical trials conducted in the E7 countries, the majority were in China.
Pseudomonas aeruginosa Infections clinical trials market, by region
For more regional insights, download a free report sample
What are the key sponsor types in the Pseudomonas aeruginosa Infections clinical trials market?
The key sponsor types in the Pseudomonas aeruginosa Infections clinical trials market are institution, company, and government. Out of them, company dominates the market.
Pseudomonas aeruginosa Infections clinical trials market, by sponsor types
For more sponsor type insights, download a free report sample
Which are the key companies in the Pseudomonas aeruginosa Infections clinical trials market?
The key companies in the Pseudomonas aeruginosa Infections clinical trials market are Gilead Sciences Inc, Novartis AG, Insmed Inc, Armata Pharmaceuticals Inc, Spexis AG, Cystic Fibrosis Foundation, Chiltern International Ltd, PARI Medical Holding GmbH, Novotech Australia Pty Ltd, and Humanigen Inc.
Pseudomonas aeruginosa Infections clinical trials market, by companies
To know more about companies, download a free report sample
Market report overview
Key regions | Europe, Northern America, Asia-Pacific, Middle East and Africa, and South and Central America |
Key countries | The US, the UK, Germany, Australia, Spain, France, Canada, Italy, Poland, and Belgium |
Key sponsor types | Institution, Company, and Government |
Key companies | Gilead Sciences Inc, Novartis AG, Insmed Inc, Armata Pharmaceuticals Inc, Spexis AG, Cystic Fibrosis Foundation, Chiltern International Ltd, PARI Medical Holding GmbH, Novotech Australia Pty Ltd, and Humanigen Inc |
Scope
The report provides:
- A snapshot of the global clinical trials landscape.
- Top level data related to the clinical trials by region, country, trial status, trial phase, sponsor type, and end point status.
- Reviews of top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company.
- All the unaccomplished trials (terminated, suspended, and withdrawn) with the reason for unaccomplishment.
- Enrollment trends for the past five years.
- Latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regards to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of Global Clinical Trials Market which helps in identifying key business opportunities.
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country level.
Novartis AG
Insmed Inc
Armata Pharmaceuticals Inc
Spexis AG
Chiltern International Ltd
Cystic Fibrosis Foundation
PARI Medical Holding GmbH
Humanigen Inc
Novotech Australia Pty Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key regions in the Pseudomonas aeruginosa Infections clinical trials market?
The key regions in the Pseudomonas aeruginosa Infections clinical trials market are Europe, North America, Asia-Pacific, Middle East and Africa, and South and Central America.
-
What are the key countries in the Pseudomonas aeruginosa Infections clinical trials market?
The key countries in the Pseudomonas aeruginosa Infections clinical trials market are the US, the UK, Germany, Australia, Spain, France, Canada, Italy, Poland, and Belgium.
-
What are the key sponsor types in the Pseudomonas aeruginosa Infections clinical trials market?
The key sponsor types in the Pseudomonas aeruginosa Infections clinical trials market are institution, company, and government.
-
Which are the key companies in the Pseudomonas aeruginosa Infections clinical trials market?
The key companies in the Pseudomonas aeruginosa Infections clinical trials market are Gilead Sciences Inc, Novartis AG, Insmed Inc, Armata Pharmaceuticals Inc, Spexis AG, Cystic Fibrosis Foundation, Chiltern International Ltd, PARI Medical Holding GmbH, Novotech Australia Pty Ltd, and Humanigen Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.